Overview:
ProductName | RosiglitazoneMaleate |
Description | Insulinsensitizer |
Purity | >98% |
CASNo. | 155141-29-0 |
MolecularFormula | C18H19N3O3S•C4H4O4 |
MolecularWeight | 473.5 |
Properties
StorageTemperature | -20ºC |
ShippingTemperature | ShippedAmbient |
ProductType | AgoNIST |
Solubility | SolubleinDMSO(3mg/ml)orDMF(10mg/ml) |
Source | Synthetic |
Appearance | Whitetooff-whitesolid |
SMILES | C2=C(CC1SC(=O)NC1=O)C=CC(=C2)OCCN(C3=CC=CC=N3)C.O=C(O)C=C/C(=O)O |
InChI | InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23) |
InChIKey | YASAKCUCGLMORW-UHFFFAOYSA-N |
SafetyPhrases | Classification:Caution:Substancenotyetfullytested.SafetyPhrases:S22-Donotbreathedust.S24/25-AvoidcontactwithskinandeyesS36/37/39-Wearsuitableprotectiveclothing,glovesandeye/faceprotection |
CiteThisProduct | RosiglitazoneMaleate(StressMarqBiosciencesInc.,VictoriaBCCANADA,Catalog#SIH-379) |
BIOLOGicalDescription
AlternativeNames | 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
ResearchAreas | CellSignaling |
PubChemID | 77999 |
ScientificBackground | RosiglitazoneisapotentagonistforPPARγwithanEC50of43nMforthehumanreceptor.Itisanti-diabetic,workingasaninsulinsensitizerbybindingtothePPARγreceptorsinfatcellsandmakingthecellsmoreresponsivetoinsulin. |
References | 1.WernerA.L.,&TravagliniM.T.(2001)Pharmacotherapy.21(9):1082-99. 2.McMorranM.,andVuD.(2001)CMAJ.165(1):82-3,86-7. 3.MalinowskiJ.M.&BolestaS.(2000)Clin.Ther.22(10):1151-68. 4.Cheng-LaiA.,&LevineA.(2000)HeartDis.2(4):326-33. 5.KnockG.A.,etal.(1999)Eur.J.Pharmacol.368(1):103-9. 6.BalfourJ.A.,&PloskerG.L.(1999)Drugs.57(6):921-30. 7.ParksD.J.,etal.(1998)Bioorg.Med.Chem.Lett.8(24):3657-8. |
ProductImages
ChemicalstructureofRosiglitazoneMaleate(SIH-379),aInsulinsensitizingagent.CAS#:122320-73-4.MolecularFormula:C18H19N3O3S.MolecularWeight:357.4g/mol.
ProductCitations(0)
Currentlytherearenocitationsforthisproduct.